Skip to main content
. 2024 Sep 25;16(2):528–535. doi: 10.1007/s13193-024-02099-2

Table 2.

Sites of relapse with the corresponding treatment for the analyzed cohort

Site of relapse Recurrence treatment Total
Chemotherapy Surgery CRS + / − HIPEC Best supportive care
Peritoneal 18 0 7 12 37
31.0% 0.0% 12.1% 20.7% 63.8%
Visceral 3 2 0 0 5
5.2% 3.4% 0.0% 0.0% 8.6%
Locoregional 8 7 0 1 16
13.8% 12.1% 0.0% 1.7% 27.6%
Total 29 9 7 13 58
50.0% 15.5% 12.1% 22.4% 100.0%

CRS cytoreductive surgery, HIPEC hyperthermic intra-peritoneal chemotherapy